Off Script: A Pharma Manufacturing Podcast

Inside the FDA’s fateful Alzheimer’s decision

March 19, 2021

If Biogen’s controversial aducanumab is approved, it could become the best-selling drug of all time — and it’s a drug that has only shown modest efficacy. Here’s more on why the Alzheimer’s pipeline is primed for such a remarkable situation.

Read the transcript: 

Podbean App

Play this podcast on Podbean App